Sign inJoin waitlistJoin the waitlist

Adam Burgoyne

Medical Oncologist · University of California (San Diego) Medical Center

Credentials: · · · ·

History

University of California (San Diego) Medical Center
Present

University of Maine
2011–2013
Case Western Reserve University School of Medicine
2007–2011
Internal Medicine
University of California (San Diego) Medical Center
2008–2011

Research

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 829 citations
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Nature Medicine · 2022 · 560 citations
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Journal of the National Comprehensive Cancer Network · 2023 · 191 citations

Jason Sicklick
22 papers · 3 as a resident
Paul Fanta
12 papers
Sudeep Banerjee
10 papers · 10 as a resident
Kate Kelley
6 papers
MH
Michael Heinrich
5 papers
Adam Yopp
4 papers
CC
Christopher Corless
4 papers
JT
Jorge De La Torre
4 papers · 4 as a resident
MH
Mojgan Hosseini
4 papers
Shu Kato
4 papers
Al Benson
3 papers
Alan Venook
3 papers

Grants

A Phase I Study of a Dual PI3K/BRD4 Inhibitor, SF1126 in the Treatment of Hepatocellular Carcinoma IDE: 74,551
Food and Drug Administration · R01
Contact PI · $250K · University of California, San Diego
2016–2020

Clinical trials

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Principal investigator · Active not recruiting · Phase 1
University of California, San Diego
2025–2027
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
Principal investigator · Completed · Phase 2
Adam Burgoyne, MD, PhD
2018–2024
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030